Bibliografía científica seleccionada.

Categoría: Tecnología

Publicaciones científicas seleccionadas.

  • Saraiva SM, Castro-López V, Pañeda C, Alonso MJ. Synthetic nanocarriers for the delivery of polynucleotides to the eye. Eur J Pharm Sci. 2017 Mar 2. pii: S0928-0987(17)30133-1. doi: 10.1016/j.ejps.2017.03.001
  • Bleau AM, Vargas B, Jiménez AI, Pañeda C. Chapter title: Managing Intraocular pressure: Innovation in Glaucoma Management. In Glaucoma and Intraocular Pressure Dynamics. ISBN 978-953-51-4913-2. Ed. In Tech. 2016
  • Benítez Del Castillo JM, Moreno-Montañés J, Jiménez-Alfaro I, Muñoz-Negrete FJ, Turman K; Palumaa K, Sádaba B, González MV, Ruz V, Vargas B, Pañeda C, Martínez T, Bleau AM and Jimenez AI. Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease. IOVS, 2016; In press.
  • Biochemistry, Genetics and Molecular Biology » "RNA Interference", book edited by Ibrokhim Y. Abdurakhmonov, ISBN 978-953-51-2272-2. Chapter 12: Preclinical Development of RNAi-Inducing Oligonucleotide (link)
  • Martínez T, Jiménez AI, Pañeda, C. Short-interference RNAs: becoming medicines. EXCLI Journal, 2015. (link)
  • Pañeda C, Gonzalez V, Martínez T, Ruz V, Vargas B and Jiménez AI. RNAi based therapies for ocular conditions. In Proceedings of the 11th ISOPT, 2014, 25-30, Medimond, Bologna, Italy.
  • Moreno-Montañés J, Sádaba B, Ruz V, Gómez-Guiu A, Zarranz J, González MV, Pañeda C, Jimenez AI. Phase I Clinical Trial of SYL040012, a Small Interfering RNA Targeting β-Adrenergic Receptor 2, for Lowering Intraocular Pressure. Mol Ther. 2014, 22(1):226-32.
  • Martínez T, González V, Roehl I, Wright N, Pañeda C, Jiménez AI. In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol Ther, 2014, 22(1):81-91.
  • Martinez-Garcia C, Martínez T, Pañeda C, Gallego P, Jimenez AI, Merayo J. Differential expression and localization of transient receptor potential vanilloid 1 in rabbit and human eyes. Histol Histopathol, 2013, 28(11):1507-16.
  • Martínez T, Wright N, López-Fraga M, Jiménez AI, Pañeda C. Silencing human genetic diseases with oligonucleotide-based therapies. Hum Genet, 2013, 132(5):481-93.
  • Pañeda C. SYL040012, a siRNA for the treatment of glaucoma. Acta Ophthalmologica 2013; Volume 91, Issue Supplement s252, page 0, August 2013.
  • RNA Interference-Based Therapeutics: Harnessing the Powers of Nature. Martinez T, Wright N, Pañeda C, Jimenez AI, Lopez-Fraga M. in: Drug Development. ISBN 978-953-307-257-9 Ed. InTech. 2011.“Recent Advances in Ocular Nucleic Acid-Based Therapies: The Silent Era.” Pañeda C, Martínez T, Wright N, Jimenez AI. In: Ocular Diseases. ISBN 978-953-51-0761-3. Ed. In Tech, 2012.
  • López-Fraga M, Martínez T, Jiménez AI. RNA interference technologies and therapeutics: from basic research to products. BioDrugs. 2009, 23(5): 305-32. 
  • López-Fraga M, Wright N, Jiménez AI. RNA interference-based therapeutics: new strategies to fight infectious disease. Infect Disord Drug Targets. 2008, 8(4): 262-73.